Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0584

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) ; volume:100 ; number:6 ; day:27 ; month:4 ; year:2021 ; pages:1463-1471 ; date:6.2021
Annals of hematology ; 100, Heft 6 (27.4.2021), 1463-1471, 6.2021

Creator: Hecht, Anna
Meyer, Julia A.
Jann, Johann-Christoph
Sockel, Katja
Giagounidis, Aristoteles
Götze, Katharina S.
Letsch, Anne
Haase, Detlef
Schlenk, Richard Friedrich
Haferlach, Torsten
Schafhausen, Philippe
Bug, Gesine
Lübbert, Michael
Thol, Felicitas
Büsche, Guntram
Schuler, Esther
Nowak, Verena
Obländer, Julia
Fey, Stephanie
Müller, Nadine Zoé
Metzgeroth, Georgia
Hofmann, Wolf-Karsten
Germing, Ulrich
Nolte, Florian
Reinwald, Mark
Nowak, Daniel

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00277-021-04492-1

URN: urn:nbn:de:101:1-2021091219065236219991

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Other Objects (12)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

Hochschulschrift

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

Hochschulschrift

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

Hochschulschrift

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Related objects

Reset password